China Securities Co.,Ltd.: Policy encouragement + new technology promotion + overseas opportunities create new chances, maintaining a bullish outlook on the Innovative Drugs industry.

National policies encourage the development of Innovative Drugs, new technologies promote the rapid growth of the Industry, new opportunities arise for going overseas, and there is a continuous Bullish outlook for the Innovative Drugs Industry.

Zhitong FinanceJan 20 18:54 ET

CSPC PHARMA (01093.HK): Regorafenib tablets have obtained pharmaceutical registration approval.

On January 20, Glonghui reported that CSPC PHARMA (01093.HK) announced that the developed Regorafenib tablets (40mg) have received the drug registration approval from the National Medical Products Administration of China, and are considered to have passed the consistency evaluation of generic drug quality and efficacy. Regorafenib is a small molecule oral multi-target kinase inhibitor, suitable for treating patients with metastatic colorectal cancer (mCRC) who have previously received chemotherapy based on fluorouracil, oxaliplatin, and irinotecan, as well as patients who have previously received or are unsuitable for anti-VEGF treatment or anti-EGFR treatment (RAS wild-type).

Gelonghui FinanceJan 20 05:18 ET

Express News | CSPC Pharmaceutical - Regorafenib Tablets Obtains Drug Registration Approval From Nmpa China

ReutersJan 20 05:16 ET

WuXi AppTec leads the surge of Hong Kong stock pharmaceutical shares, while Global Biomedical investment and financing shows signs of recovery.

① The WuXi AppTec system leads the rise of Hong Kong pharmaceutical stocks, which Bullish factors are worth paying attention to? ② Global Biomedical investment and financing has seen some recovery, how do Institutions view it?

cls.cnJan 20 03:30 ET

Sinolink: The policy inflection point is clear, suggesting to start increasing allocation in the pharmaceutical sector.

In the segmented Industry, it is recommended to focus on allocating resources to Innovative Drugs and left-side Sectors (such as Medical Device, Traditional Chinese Medicine, Consumer Medical, chain pharmacies, etc.) for opportunities in reverse situations of individual stocks as the two main lines.

Zhitong FinanceJan 20 00:51 ET

Zhao Yin International: The Class B medical insurance catalog will be implemented within the year, Innovative Drugs will open up domestic payment space.

Zhao Yin International is Bullish on the valuation recovery of the Medical and Pharmaceutical Industry.

Zhitong FinanceJan 19 20:38 ET